Sugi Predict

Sugi Predict / Compounds / SCHEMBL660764

SCHEMBL660764

SCHEMBL660764

O=C(O)CC(CC(=O)O)c1ccc(F)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 1/20 0.54
▸ FNTB P49356 1/20 0.54
▸ GABBR2 O75899 5/20 0.52
▸ GABBR1 Q9UBS5 5/20 0.52
▸ LMNA P02545 2/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ ADORA3 P0DMS8 1/20 0.52
▸ NFKB1 P19838 1/20 0.52
▸ DRD3 P35462 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ FFAR1 O14842 2/20 0.51
▸ ITGB3 P05106 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7334847 0.98 FNTA (0.52) FNTAFNTBGABBR2GABBR1LMNA
SCHEMBL28316668 0.90 FFAR1 (0.47) FNTAFNTBGABBR2GABBR1LMNA
SCHEMBL658678 0.89 FNTA (0.50) FNTAFNTBGABBR2GABBR1LMNA
SCHEMBL16249736 0.89 GABBR2 (0.61) FNTAFNTBGABBR2GABBR1LMNA
SCHEMBL351702 0.88 GABBR2 (0.70) FNTAFNTBGABBR2GABBR1LMNA
SCHEMBL5378079 0.88 FFAR1 (0.52) FNTAFNTBGABBR2GABBR1LMNA
SCHEMBL351502 0.88 GABBR2 (0.70) FNTAFNTBGABBR2GABBR1LMNA
SCHEMBL6780687 0.87 FNTA (0.48) FNTAFNTBGABBR2GABBR1LMNA
SCHEMBL6581020 0.86 ALDH1A1 (0.55) FNTAFNTBGABBR2GABBR1LMNA
SCHEMBL6581023 0.86 ALDH1A1 (0.55) FNTAFNTBGABBR2GABBR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113564144-B Lipase mutant and application thereof 上海奥博生物医药股份有限公司 2025-04-04 — — CN claimed
CN-117550943-A Based on CO 2 Method for participating in controllable synthesis of polycarboxylic acid compounds 四川大学 2024-02-13 — — CN disclosed
CN-117247317-A Based on CO 2 Method for synthesizing dicarboxylic acid/tricarboxylic acid compound 四川大学 2023-12-19 — — CN disclosed
CN-105132393-B A kind of deep-sea salt tolerant, the expression and purifying of alkaline-resisting albumen esterase, crystal structure and its application 复旦大学 2018-08-24 — — CN disclosed
CN-104710348-B Preparation method of 3,5-dicyano-4-p-fluorophenyl-2,6-dioxopiperidine 衢州学院 2017-04-26 — — CN disclosed
EP-2349999-B1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIV SAARLAND (DE) 2016-01-27 — — EP disclosed
US-8912186-B2 Allosteric protein kinase modulators UNIVERSITAET DES SAARLANDES (DE) 2014-12-16 — — US disclosed
CN-103215238-B Marine bacterial novel esterase, as well as preparation method and application thereof SECOND INST OCEANOGRAPHY SOA 2014-09-03 — — CN disclosed
CN-103215238-A Marine bacterial novel esterase, as well as preparation method and application thereof SECOND INST OCEANOGRAPHY SOA 2013-07-24 — — CN disclosed
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2012-02-23 — — US disclosed
EP-1411052-A1 BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-04-21 — — EP disclosed
US-6716985-B2 ALCOHOLISM, PSYCHOLOGICAL DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2004-04-06 — — US disclosed
EP-1289983-A2 HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS Pharmacia Corporation (US) 2003-03-12 — — EP disclosed
US-6489347-B1 NOVEL INTERMEDIATE CARBOXALDEHYDES FOR PHARMACEUTICAL PRODUCTS WITH ANTIDEPRESSANT AND ANTI-PARKINSON PROPERTIES SMITHKLINE BEECHAM PLC (GB) 2002-12-03 — — US disclosed
US-20020133023-A1 Heteroarylalkanoic acids as integrin receptor antagonists PHARMACIA CORPORATION 2002-09-19 — — US disclosed
US-20020133011-A1 Novel process SMITHKLINE BEECHAM PLC 2002-09-19 — — US disclosed
WO-2001096334-A2 HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS PHARMACIA CORPORATION (US) 2001-12-20 — — WO disclosed
EP-0986389-A4 NOVEL PROCESS SMITHKLINE BEECHAM CORP (US) 2001-09-12 — — EP disclosed
EP-0986389-A1 NOVEL PROCESS SMITHKLINE BEECHAM CORPORATION (US) 2000-03-22 — — EP disclosed
WO-1998053824-A1 NOVEL PROCESS SMITHKLINE BEECHAM CORPORATION (US) 1998-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020133023-A1 Heteroarylalkanoic acids as integrin receptor antagonists ITGA5, ITGA2B, ITGAV FNTA 818/4885FNTB 764/4885GABBR2 164/4885
US-20020133011-A1 Novel process HTR1A, HTR4, MAOA FNTA 4031/4885FNTB 3464/4885GABBR2 1452/4885
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS AURKC, AURKA, AURKB FNTA 944/4885FNTB 1890/4885GABBR2 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.